The United States nebulizer market is set to grow from US$ 466.55 million in 2024 to US$ 730.62 million by 2033, with a CAGR of 5.11%. This growth is driven by the rising prevalence of respiratory ...
The Breathing Association, a Columbus-based nonprofit that helps 15,000 people with utility costs, faces closure due to the ...
Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan ...
About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the ...
As cooler temperatures and shifting air quality arrive, many families notice changes in their breathing. Dry air, allergens, ...
Since 2015, the Community Paramedic Program has helped patients who are at higher risk of falling through the cracks after hospitalization. Ideally, patients recover best at home after they are ...
Oral and inhaled biologics are gaining R&D investment due to patient acceptance and potential for home administration, with ...
AstraZeneca's hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 ...
The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback